Patients with relapsing, primary progressive, and secondary progressive MS were administered the Tower of London and the Stroop Color-Word Interference Test, yielding several measures of executive function and speeded information processing. MS patients' performance was compared with healthy controls and with a clinical control group consisting of patients with rheumatoid arthritis. The MS patients performed the tests more slowly, but did not differ from either group of controls on measures of executive function. Slowing in the speed of information processing was characteristic of MS patients across two basic tasks differing in terms of controlled versus automatic processing and in terms of whether or not rapid responding was an explicit feature of successful performance. Although evident in all subtypes, this slowing was more pronounced in secondary progressive patients and somewhat less pronounced in primary progressive patients. Furthermore, the slowing was unrelated to patients' disability status or level of depression.
Estimates of the prevalence of cognitive impairment among patients with multiple sclerosis (MS) range between 43 and 65% (Heaton, Nelson, Thompson, Burks, & Franklin, 1985; McIntosh-Michaelis et al., 1991; Peyser, Edwards, Poser, & Filskov, 1980; . Severe dementia occurs in far fewer cases. Only 20-30% of patients showing evidence of cognitive impairment on neuropsychological testing exhibit a level of dementia that notably interferes with occupational or social functioning (Rao, Hammeke, McQuillen, Khatri, & Lloyd, 1984; Rao, Leo, Ellington et al., 1991) . On the basis of cross-sectional studies, cognitive impairment appears to be unrelated to the length of illness and only modestly related to the extent of physical disability (Beatty, Goodkin, Hertsgaard, & Monson, 1990; Filippi et al., 1994; Fischer et al., 1994; Hämäläinen & Ruutiainen, 1999; Ivnik, 1978; Lynch, Denney, & Parmenter, 2005; Marsh, 1980; Peyser et al., 1980; Rao, Leo, Ellington et al., 1991; Wishart & Sharpe, 1997) .
Several investigators have pointed out that the cognitive impairment observed in MS is generally consistent with a pattern of subcortical dementia (Caltagirone, Carlesimo, Fadda, & Roncacci, 1991; Filley, Heaton, Nelson, Burks, & Franklin, 1989; Rao, 1996) . We recently compared patients with relapsing and primary progressive forms of MS using a battery of measures assembled on the basis of this assertion (Denney, Lynch, Parmenter, & Horne, 2004) . Relative to healthy controls, the patients had significant differences on only one of the central features of subcortical dementia -the speed of information processing. The measures loading on this factor were derived from two tests in the battery that have also been used in several previous studies of MS: the Tower of London (Arnett et al., 1997; Arnett, Higginson, & Randolph, 2001; Foong et al., 1997 ) and the Stroop Color-Word Interference Test (Pujol et al., 2001; Scarrabelotti & Carroll, 1999; Vitkovitch, Bishop, Dancey, & Richards, 2002) . Relative to controls, patients required longer times to plan their solutions on the Tower and completed fewer items on all three trials of the Stroop (i.e., word reading, color naming, and color-word naming). Furthermore, we showed that these differences tended to be greater for relapsing patients than for those with primary progressive MS. One objective of the present study was to follow up on these findings.
Our previous study did not include a sample of secondary progressive patients, the third common subtype of MS. Such patients have a prior history of relapsing disease that has subsequently devolved to a progressive course. Secondary progressive MS can therefore be considered a more advanced stage of MS, one that might be expected to present with greater cognitive impairment. In contrast, patients with primary progressive MS have no prior history of relapsing disease and therefore a comparison between them and relapsing patients does not necessarily entail a difference in chronicity.
Despite the potential confounds, a comparison of all three common subtypes of MS is desirable. In the existing literature pertaining to cognitive impairment, only three studies (de Sonneville et al., 2002; Gaudino, Chiaravolloti, DeLuca, & Diamond, 2001; Huijbregts et al., 2004) present such a comparison. The more common practice has been to compare relapsing and chronic progressive patients, the latter group combining both primary and secondary progressive patients. Typically in these studies, patients with chronic progressive MS are found to have more pronounced impairment than those with relapsing disease (Beatty, Goodkin, Monson, & Beatty, 1989; Beatty, Goodkin, Monson, Beatty, & Hertsgaard, 1988; Grossman et al., 1994; Heaton et al., 1985; Kujala, Portin, Revonsuo, & Ruutiainen, 1995; Rao et al., 1984) . In the few instances where patients with primary and secondary progressive MS have been distinguished, some investigators have reported greater cognitive impairment in those with secondary progressive MS (Comi et al., 1995; Gaudino et al., 2001; Huijbregts et al., 2004) ; others have reported essentially no differences between these two forms of progressive MS (de Sonneville et al., 2002; Foong et al., 2000) . Primary progressive patients in our previous study (Denney et al., 2004) had less slowing on the measures of information processing speed than those with relapsing MS. Therefore, in the present study, we expected to also find less slowing among primary progressive patients compared to those with secondary progressive MS.
Arnett and his colleagues have argued that depression makes an important contribution to the cognitive deficits apparent in MS patients. They showed that depressed MS patients performed more poorly than non-depressed MS patients on tests of speeded information processing (Arnett et al., 1999) and executive function (Arnett et al., 2001 ). In our previous study (Denney et al., 2004) , we also found that depression impacted patients' performance on measures of executive function. Differences between patients and controls were no longer significant when their scores on these measures were adjusted for depression and fatigue through an analysis of covariance, and depression emerged as a significant covariate in these analyses. However, in contrast to Arnett's findings, statistically controlling for depression and fatigue had no impact on the outcome with respect to measures of speeded information processing. Covarying for depression and fatigue did not notably diminish substantial differences on these measures. The present study offered a further opportunity to investigate the impact of depression on measures of executive function and speeded information processing.
Method

Subjects
Patients with clinically definite MS (McDonald et al., 2001) were recruited for the study during the course of their regular appointments in the MS clinic of a university medical center. All were patients of the same board-certified neurologist (SGL), an MS specialist who had provided care for at least one year prior to the study. Exclusion criteria were (a) history of alcohol or drug abuse, head injury with loss of consciousness, schizophrenia or bipolar disorder, learning disability, or any neurological disorder other than MS, (b) significant visual or motor impairment that would interfere with cognitive testing, (c) current exacerbation in the patient's illness, or (d) residence over 450 miles away from the medical center thus complicating travel to the patient's home to conduct testing. Qualifications were judged on the basis of medical chart review and interview of the patient during the consultation. Of the patients who met criteria and were invited to participate, 15 declined the invitation. The recruited sample consisted of 20 patients (15 females, 5 males) with relapsing MS, 20 (9 females, 11 males) with primary progressive MS, and 22 (17 females, 5 males) with secondary progressive MS. One female and one male patient from the secondary progressive group were too impaired to complete the testing, and their partial data were not included.
The remaining 60 patients (40 females, 20 males) ranged in age from 26 to 79 (M = 48.4). Years of education ranged from 9 to 22 (M = 15.2). Length of illness ranged from 1 to 30 years (M = 10.8), and disability based on the Expanded Disability Status Scale (EDSS: Kurtzke, 1983 ) ranged from 1.0 to 8.5 (M = 5.1). The three groups differ significantly in length of illness, with secondary progressive patients having been diagnosed for a longer time (M = 16.7) than either primary progressive (M = 6.4) or relapsing patients (M = 9.4). Secondary progressive patients also had significantly greater disability (M = 6.5) than primary progressive (M = 4.8) or relapsing patients (M = 4.2). All patients were currently taking MS-related medications at the time of the study.
For comparison purposes, a sample of 20 patients with rheumatoid arthritis (15 females, 5 males) and a sample of 24 healthy control subjects (17 females, 7 males) were also recruited for this study. Rheumatoid arthritis (RA) was selected as a clinical control because (a) it is an autoimmune disease resulting in physical disability, although with no known involvement of the central nervous system, (b) patients with RA commonly experience comparable symptoms of pain and fatigue that might impact performance on cognitive tests, and (c) patients with RA often take similar types of medication (e.g., anti-inflammatories; immunosuppressants) with potential side effects upon cognitive performance. The RA patients were recruited during their regular appointments at the Rheumatology clinic in the same medical center. Qualification for the study was determined on the basis of a medical chart review and interview of the patient during the consultation by a board-certified rheumatologist. The RA sample consisted of 20 patients who ranged in age from 40 to 86 (M = 57.4) and had completed from 12 to 20 years of education (M = 14.9). They had been diagnosed with RA for 1-28 years (M = 13.1) and, like the MS patients, all were currently on medications related to their disease.
The healthy controls ranged in age from 26 to 58 (M = 46.4) and had completed from 12 to 20 years of education (M = 15.5). Control subjects were recruited through newspaper ads, posters, and contacts with personnel at the medical center.
Measures
The Tower of London
This test of planning and strategic problem solving was computerized for the present study (Krikorian, Bartok, & Gay, 1994) . In the upper portion of the monitor, the computer displayed three colored disks arranged on three pegs. In the lower portion of the screen, the computer displayed a model with the disks in a different arrangement on the pegs. The subject's task was to move the disks in the upper display so they matched the arrangement in the bottom display and to do so in a specified number of moves. Twelve problems were presented, graduated in difficulty from those that could be solved in two moves to those requiring a sequence of five moves. At the beginning of each problem, subjects were told the number of moves permitted to solve the problem. Subjects were allowed three attempts to solve each problem in the specified number of moves and were awarded 3, 2, or 1 points for a correct solution on the first, second, or third attempt. The TOL point score was the sum of the points earned across the 12 problems. On each trial, the computer also measured the length of time between the display of the problem and the subject's first move ("planning time") and the length of time between the subject's first and last moves on that trial ("execution time"). The planning times for the initial presentation of each problem (regardless of whether the subject succeeded in solving the problem during this initial attempt) were averaged across the 12 problems; this measure was termed "initial planning time." The execution times for trials in which the subject succeeded in correctly solving the problem were also averaged across the 12 problems; this measure was termed "correct execution time."
The Stroop Color-Word Interference Test
We designed a computerized version of the Stroop for use in the present study (Stroop, 1935) . The test consisted of three 45-s trials during which the subject first read color words (word reading), then named the color of four Xs (color naming), and finally, named the color of the letters of color words (color-word naming), appearing in the center of the computer screen. In the color-word naming trial, all the stimuli were incongruent (e.g., the word "GREEN" printed in blue letters). A brief, eight-stimulus practice set was presented before the start of each trial. Subjects gave a verbal response to the stimulus (i.e., read the word or named the color) and then pressed the space bar to display the next stimulus. The computer timed the trial and recorded the number of stimuli completed during the 45-s trial. In addition to the word reading, color naming, and color-word naming scores, an interference score was derived by subtracting the color-word naming score from the color naming score. Because the number of errors committed was very small for all subjects, errors were not analyzed in this study.
Self-report questionnaires
In addition to the cognitive measures, subjects' general levels of fatigue and depression during the preceding week were assessed using the Fatigue Severity Scale (FSS: Krupp, LaRocca, Muir-Nash, & Steinberg, 1989 ) and the Center for Epidemiologic Studies-Depression Scale (CES-D: Radloff, 1977) . In addition, the MS and RA patients completed the Health Assessment Questionnaire (HAQ: Hakala, Nieminen, & Manelius, 1994) , an 18-item self-report measure evaluating the impact of patients' physical disability on common daily activities (e.g., driving a car, standing up from a chair, using a pen or pencil). Each item was rated on a scale from 0 ("able to do without difficulty") to 3 ("unable to do").
Procedure
This study was approved by the Human Subjects Committee of the University of Kansas Medical Center. While the patient was in the clinic, a research assistant explained the study and obtained informed consent. Subjects were tested during a subsequent appointment conducted either in the clinic or in the subject's home. The location for testing was left to the convenience of the subject, and most elected to be tested at home. The testing session lasted about 45 min and began with the subject completing the self-report questionnaires, followed by the Tower and then the Stroop.
Results
Descriptive data characterizing the three subgroups of MS patients, the RA patients, and the healthy controls are presented in Table 1 . EDSS scores were not available for the RA patients; the HAQ was the only measure of disability available for all patients. However, for the MS patients, scores on the EDSS and HAQ were highly correlated, r(50) = .86, P < .001. The overall mean for the MS patients on the HAQ (M = 11.1) did not differ significantly from that of the RA patients (M = 8.6), t(70) < 1, P = .40. This result was consistent with our overall impression that MS and RA patients in this study were generally equivalent in terms of physical disability, with most patients exhibiting only mild symptoms. However, a one-way analysis of variance comparing the three subgroups of MS patients and the RA patients was significant, F(3, 68) = 8.3, P < .001, because the patients with secondary progressive MS had substantially higher disability scores than each of the other three patient groups (all Ps < .001). The three subgroups of MS patients and the RA patients were also compared in terms of the number of medications they were taking with known or suspected impact upon cognitive performance. No differences were found, F(3, 68) = 2.03, P = .12, and none of the paired comparisons between separate groups of patient were significant. When particular classes of drugs were examined, three differences between MS patients and RA patients were noted: RA patients were more likely to be prescribed steroid medications, χ 2 = 26.2, d.f. = 3, P < .001; MS patients were more likely to be prescribed antidepressant medications, χ 2 = 10.0, d.f. = 3, P = .02, and, not surprisingly, MS-related immunomodulatory agents, χ 2 = 17.4, d.f. = 3, P = .001. No differences were found for the other classes of drugs (i.e., anticonvulsants, anti-spasmodics, anxiolytics, narcotics). Although the groups differed it terms of certain classes of drugs, the use of RA patients as a control for medication appears to have been generally successful.
Females outnumbered males by at least 2:1 in all groups except the primary progressive MS group. The composition with respect to gender did not differ significantly across the groups, χ 2 (2, N = 100) = 6.3, P = .18. The five groups also did not differ in education level, F(4, 99) = 1.2, P = .32. Significant differences were found for age, F(4, 99) = 6.6, P < .001, depression, F(4, 96) = 2.7, P = .03, and fatigue, F(4, 97) = 15.4, P < .001. RA patients and primary progressive MS patients were older than relapsing MS patients. RA patients were also older than the healthy controls. There were no differences between the patient groups in terms of depression, but the primary progressive MS patients had significantly higher depression scores than the healthy controls. All four patient groups had significantly higher fatigue scores than the controls, with the primary progressive patients also reporting greater fatigue than the RA patients. Because differences such as these might affect the outcome on the cognitive measures, we used age, gender, education level, depression, and fatigue scores as covariates in the subsequent analyses, thereby statistically controlling for differences between groups on these extraneous variables.
The cognitive variables were entered collectively into a multivariate analysis of covariance. Age was the only significant covariate, Wilks' λ = .84, F(6, 83) = 2.6, P = .02, although depression was nearly significant, Wilks' λ = .87, F(6, 83) = 2.0, P = .08. The main effect pertaining to differences between the five groups of subjects was significant, Wilks' λ = .52, F(24, 291) = 2.5, P < .001; partial η 2 = .15, and this was followed up with univariate analyses of covariance applied to each of the cognitive variables. With the exception of the point scores on the Tower and the interference score on the Stroop (both P values > .21), significant differences were found on each of the cognitive measures: Tower of London: initial planning times, F(4, 89) = 2.5, P = .045, partial η 2 = .10; correct execution times, F(4, 89) = 32.8, P = .007, partial η 2 = .14; Stroop: word reading, F(4, 90) = 2.8, P = .03, partial η 2 = .11; color naming, F(4, 90) = 5.9, P < .001, partial η 2 = .21; color-word naming, F(4, 90) = 9.9, P < .001, partial η 2 = .31. The covariate-adjusted means for all cognitive measures are presented in Table 2 . Depression was a significant covariate in the analysis of point scores on the Tower, F(1, 89) = 7.7, P = .003, partial η 2 = .080. Age was a significant covariate on planning times, F(1, 89) = 11.0, P = .001, partial η 2 = .11. No other significant covariates emerged in the univariate analyses.
The significant main effects on the various cognitive measures were analyzed further by paired comparisons performed on the covariate-adjusted scores. Relative to healthy controls, the patients in each of the four patient groups achieved significantly lower scores on all the measures derived from the Stroop. On the Tower, the three groups of MS patients had longer execution times than either the RA patients or the healthy controls. An examination of the means in Table 2 reveals that the greatest deficits occurred for the secondary progressive MS patients. In addition to requiring more time for both planning and execution on the Tower and achieving lower scores on all three trials of the Stroop relative to healthy controls (all Ps < .05), the secondary progressive MS patients also differed from the RA group on planning time (P < .05), execution time (P < .05), color naming (P < .09), and color-word naming (P < .05). They also differed from the primary progressive MS patients on planning time (P < .06) and from the relapsing MS patients on color-word naming (P < .07).
To compare the present results with those of Arnett et al. (1999 Arnett et al. ( , 2001 ), a median score on the CESD was used to divide MS patients into "non-depressed" (CESD < 16) and "depressed" groups (CESD ≥ 16). The two groups did not differ in terms of disease subtype, χ 2 = 1.7, d.f. = 2, P = .42. Non-depressed and depressed MS patients were compared with the healthy control group. (Four of the healthy control subjects were dropped from this analysis because their CESD scores exceeded 15.) The performance of these three groups on the full array of cognitive measures was analyzed with a multivariate analysis of covariance, with age, gender, education level, and fatigue scores serving as covariates. The only covariate that was significant in this analysis was age, Wilks' λ = .80, F(6, 63) = 2.6, P = .03. The main effect pertaining to differences between the three groups of subjects was also significant, Wilks' λ = .54, F(12, 126) = 3.7, P < .001; partial η 2 = .26, and this was followed up with univariate analyses of covariance applied to each of the cognitive measures. With the exception of the interference scores on the Stroop, significant differences between the three groups of subjects were found on each of these cognitive measures: Tower: point score, F(2, 69) = 3.4, P = .038; initial planning times, F(2, 69) = 3.9, P = .026, partial η 2 = .10; correct execution times, F(2, 69) = 4.5, P = .015, partial η 2 = .12; Stroop: word reading, F(2, 69) = 4.5, P = .015, partial η 2 = .11; color naming, F(2, 69) = 10.7, P < .001, partial η 2 = .24; color-word naming, F(2, 69) = 13.9, P < .001, partial η 2 = .29. Paired comparisons revealed that both the depressed and non-depressed groups of MS patients differed significantly from healthy controls on every cognitive measure except the point score from the Tower. On this measure, only the depressed MS patients differed significantly from the healthy controls. The performance of the depressed MS patients did not differ from that of non-depressed MS patients on any of the cognitive measures. The covariate-adjusted means for all cognitive measures are presented in Table 3 . Inspection of these means reveals that, except for the point score on the Tower, the performance of the depressed and non-depressed MS groups was highly similar.
Discussion
The present study was designed (a) to examine the cognitive performance of patients with the three most common subtypes of multiple sclerosis, (b) to compare this performance not only with that of healthy controls but also with a clinical control group consisting of patients with rheumatoid arthritis, and (c) to examine the impact of depression on the cognitive performance of the MS patients. The tests composing the cognitive battery offered measures of speeded information processing and measures more readily aligned with core executive functions. The measures of executive function consisted of the point score on the Tower, reflecting the ability of the subject to plan a sequence of moves leading to a successful solution, and the interference score from the Stroop, indicating the extent to which the subject was able to deploy attention effectively and to avoid distraction by salient but irrelevant features of the stimulus. The measures of speeded information processing included the scores on the separate trials of the Stroop (i.e., word reading, color naming, and color-word naming) and the initial planning times recorded during the Tower. We also examined execution times for the trials on which the subject succeeded in correctly solving the 12 problems composing the Tower. As we discuss later, correct execution time may also reflect information processing speed, but is confounded by other factors.
In terms of comparisons between MS patients and healthy controls, the results of the present study are very similar those of our previous work (Denney et al., 2004) . In both studies, with groups equated with respect to age, gender, education, depression, and fatigue, no differences between patients and healthy controls were found on measures of executive function. One such measure, the point score derived from the Tower, was identical in the two studies, and in both studies, depression emerged as a significant covariate. The interference measure on the Stroop was computed in a slightly different way between the two studies, but in neither instance were significant differences found between MS patients and controls on this measure. On the other hand, substantial differences occurred on all measures of speeded information processing: the word reading, color naming, and color-word naming scores from the Stroop, and the planning times and execution times from the Tower.
Our conclusion is that a generalized slowing in the speed of information processing is a prominent feature of the cognitive impact of multiple sclerosis. We do not mean to suggest this is an original conclusion. Generalized slowing in the speed of information processing has been demonstrated by numerous investigators using a variety of measures, such as the Sternberg task (Archibald & Fisk, 2000; Litvan, Grafman, Vendrell, & Martinez, 1988; Rao, St. Aubin-Faubert, & Leo, 1989) , the Paced Auditory Serial Addition Test (DeLuca, Johnson, & Natelson, 1993; Demaree, DeLuca, Gaudino, & Diamond, 1999; Hohol et al., 1997; Kujala, Portin, Revonsuo, & Ruutiainen, 1994; Litvan et al., 1988; Paul, Beatty, Schneider, Blanco, & Hames, 1998; Snyder, Cappelleri, Archibald, & Fisk, 2001) , symbol-digit tests (Beatty et al., 1988 (Beatty et al., , 1989 Paul et al., 1998) , tests of word fluency and simple naming (Beatty et al., 1988; Beatty & Monson, 1994; Ryan, Clark, Klonoff, Li, & Paty, 1996) , alphanumeric sequencing (Grigsby, Kaye, & Busenbark, 1994; Heaton et al., 1985) , and the Stroop Test (Pujol et al., 2001; Scarrabelotti & Carroll, 1999; Vitkovitch et al., 2002) . The present study extends this body of research in terms of both generality and specificity.
As in our previous study, slowing in the speed of information processing was observed on tasks involving automatic processing (e.g., the word reading and color naming trials of the Stroop) as well as those involving more controlled processing (e.g., the color-word naming trial), and occurred regardless of whether speed was an explicit feature of successful performance (e.g., the Stroop) or was recorded covertly while the patient attended to other demands of the task (e.g., the Tower). Furthermore this slowing was observed in all three subtypes of MS examined in the present study. Across all measures, the effect was more pronounced among patients with secondary progressive MS, and in two instances (planning times and color-word naming), near significant differences were found between secondary progressive patients and those with other subtypes of MS. The secondary progressive patients also had significantly greater disability. However, the differences between subtypes in cognitive performance do not appear to be attributable to disability. Only one of the cognitive measures (word reading) was related to disability as indexed by the EDSS, r(58) = −.33, P = .01, or the HAQ, r(50) = −.25, P = .07. No other correlations between cognitive measures and disability measures exceeded ±.16. Relative to the other subtypes, the primary progressive patients exhibited somewhat better performance on both planning time and color naming, but cognitive "sparing" among this subtype of patients was not as clearly evident as in our previous study or that of Comi et al. (1995) . Huijbregts et al. (2004) also noted that the poorer performance by secondary progressive patients in their study was most evident on tasks which depended strongly on speed of information processing. The larger number of patients included in this study probably accounts for their finding significant differences between secondary progressive patients and other subtypes, whereas similar comparisons in the present study failed to reach significance. However, it must be noted that the two studies also diverge with respect to one point: disability accounted for much more of the variation in information processing speed in Huijbregts et al.'s results than in the present study.
With respect to specificity, the present study is one of only a few investigations to include a clinical control group, thereby providing some degree of control over possible variables associated with having a chronic and progressively disabling illness and with the use of medications that could impact ones cognitive abilities. Inspection of the means presented in Table 2 reveals that the patients with rheumatoid arthritis also tended to perform more slowly than healthy controls, but these differences were evident only on the Stroop and not on the planning and execution times recorded during the Tower. All three of the MS groups had longer execution times on the Tower compared to the RA patients, and both the relapsing and secondary progressive patients also had longer planning times. Furthermore, secondary progressive patients achieved lower scores on color naming, and color-word naming compared to the RA patients. In general, the slowing in information processing speed was more pronounced among the MS patients.
Arnett has reported differences between depressed and non-depressed MS patients on both point scores and timing measures derived from the Tower (Arnett et al., 2001 ) as well as on several capacity-demanding tasks involving speeded information processing (Arnett et al., 1999) . Based on these differences, Arnett concluded that depression was closely implicated in the cognitive deficits exhibited by MS patients. In the present study, however, the impact of depression was confined to one principal measure of executive function -the point scores on the Tower. Depression emerged as a significant covariate in the analysis of these scores, and when the MS patients were subdivided on the basis of their depression scores, depressed patients were found to have lower point scores than the healthy controls, whereas non-depressed patients did not differ from these controls. These results are consistent with the findings of our previous study (Denney et al., 2004) and indicate that depression may indeed contribute to apparent deficits in executive function among MS patients. However, we contend that the contribution of depression is largely confined to executive functions and does not extend to measures of information processing speed. In contrast to Arnett et al. (2001) , we found no evidence of depression impacting the response times on the Tower or any of the measures derived from the Stroop.
The computer program employed in the present study distinguished "planning time" and "execution time." Arnett et al. did not draw this distinction, but instead measured the total response time from the presentation of each problem to the end of the subject's attempted solution. To determine whether the difference in outcome between our study and Annett's study might be explained by the difference in the response time measures used in these two studies, we summed planning and execution times to arrive at a total response time comparable to that used by Arnett. An analysis of these combined times averaged across correctly solved trials revealed no difference between depressed (M = 49.0) and non-depressed (M = 44.6) MS patients. Both patient groups had longer combined times than healthy controls (M = 31.4), though these differences were not significant.
We believe that combining planning and execution times results in an inferior index of information processing speed. The problem lies with the measure of execution time, which is badly confounded by other factors. When the subject is involved in moving the disksas in Arnett's study, execution time is vulnerable to impairments in motor speed. When the experimenter manipulates the disks in response to the subject's verbal commands -as in the present study, execution time is still vulnerable to operator variability and delays in translating verbal directions into action. Such confounds do not apply to planning time. Here measurement occurs during the period when the patient is quietly contemplating the sequence of moves that might solve the problem. Whereas a slowing of motor performance ("bradykinesia") is a common feature of MS, the present study along with others (Archibald & Fisk, 2000; de Sonneville et al., 2002; Kujala et al., 1994) indicates that a parallel slowing in the speed of mentation ("bradyphrenia") occurring across a broad spectrum of cognitive activities is also characteristic of this disease.
